F.D.A. Approves New Obesity Drug Tirzepatide That Will Compete With Wegovynews2023-11-09T01:02:09+00:00November 9th, 2023|The New York Times|
FDA Approves Zepbound, A Drug Like Ozempic, for Weight Loss. Here’s What to Know.news2023-11-08T18:34:20+00:00November 8th, 2023|The New York Times|
Infants Are Born With Syphilis in Growing Numbers, a Sign of a Wider Epidemicnews2023-11-07T18:13:14+00:00November 7th, 2023|The New York Times|
Charity Watch Auction Stalled by Social Media Outcrynews2023-11-07T10:06:10+00:00November 7th, 2023|The New York Times|
Some Covid Vaccines Are Still Hard to Findnews2023-11-06T10:01:32+00:00November 6th, 2023|The New York Times|
Ending TB Is Within Reach — So Why Are Millions Still Dying?news2023-11-06T10:00:50+00:00November 6th, 2023|The New York Times|
Why Pharmacy Workers at CVS and Walgreens Are Protestingnews2023-11-01T10:17:07+00:00November 1st, 2023|The New York Times|
Panel Tells F.D.A. That CRISPR Sickle Cell Cure Is Safe Enough for Patientsnews2023-10-31T21:21:11+00:00October 31st, 2023|The New York Times|
F.D.A. Experts Will Vote on Safety of a Cure for Sickle Cell Diseasenews2023-10-30T20:19:43+00:00October 30th, 2023|The New York Times|
A New Sickle Cell Treatment Will Change Lives — but How Many?news2023-10-30T09:01:12+00:00October 30th, 2023|The New York Times|
